This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Strong Data From Lagova™ Phase II Clinical Study Presented During Webcast

OPKO Health, Inc. (NYSE:OPK), a multinational biopharmaceutical and diagnostics company, yesterday hosted a webcast presenting outstanding interim six-month results from a Phase 2 study of its long-acting human growth hormone product Lagova to treat pediatric growth hormone deficiency disorder (GHD).

During the webcast, Dr. Ron Rosenfeld, Chairman of OPKO Biologic’s Scientific Advisory Board and professor emeritus of Pediatrics at both Stanford University and Oregon Health and Science University, highlighted the superior interim results from the study. In particular, Dr. Rosenfeld, a pioneer in the recombinant human growth hormone field, noted that the mean height velocity achieved with each of the three different doses of Lagova administered in the study was “actually quite dramatic, ranging from 12.25 centimeters to almost 15.5 centimeters. Every child enrolled in the study experienced a significant improvement in height velocity from weekly administration of Lagova,” he noted.

“OPKO believes there is a significant market opportunity with Lagova, as compliance with daily injections is problematic. Non-compliance leads to a significant decrease in growth response in both adults and children, which is well evidenced by current clinical literature,” said OPKO’s CEO, Phillip Frost, M.D. “The outstanding interim Phase II results allow for dose selection for a Phase III study which is anticipated to start in 2015.”

Unlike other pediatric long-acting growth hormone deficiency clinical trials, the Lagova Phase II trials also included a direct comparator arm at the same population with similar baseline values. Children were given daily administration of growth hormone at a dosage of 0.24 mg/kg per week, but administered daily in a traditional manner. There was no statistically significant difference among any of the three dosage strengths of Lagova used in the study versus the comparator arm.

As any Phase III trial for a long-acting recombinant human growth hormone will likely require proof of non-inferiority against a comparator arm of daily administered growth hormone, this is an important distinction that gives OPKO great confidence in designing its non-inferiority pivotal Phase III study for Lagova. Had OPKO utilized historical database comparisons as utilized in other pediatric GHD clinical trials versus an actual comparator arm, annualized height velocity for Lagova at all three dosage strengths would have been notably superior, exceeding comparable age-matched historical controls, as published by Bakker (2008) and Ranke (2010) for the same GHD patient population by approximately 30%.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs